Developments in managing CF continue to drive dramatic improvements in survival. As
newborn screening rolls-out across Europe, CF centres are increasingly caring for cohorts of …

Inflammation plays a critical role in cystic fibrosis (CF) lung pathology and disease
progression making it an active area of research and important therapeutic target. In this …

Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF)
patients, an effect that is currently attributed to ibuprofen's anti-inflammatory properties. Yet …

Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) share molecular
mechanisms that cause the pathological symptoms they have in common. Here, we review …

When a meta-analysis consists of a few small trials that report zero events, accounting for
heterogeneity in the (interval) estimation of the overall effect is challenging. Typically, we …

Mukoviszidose (Cystic Fibrosis, CF) ist die häufigste, autosomal-rezessiv vererbte
Multisystemerkrankung. In Deutschland sind ca. 8000 Menschen betroffen. Die Erkrankung …

Introduction: Cystic fibrosis (CF) is a congenital life-limiting, orphan disease affecting 1/2500–
1/3000 people worldwide with the greatest prevalence in Europe, North America and …

Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as
follows: To assess the benefits and harms of strategies (such as altering the type and dose …

Kidney damage in cystic fibrosis (CF) patients is most commonly caused by antibiotics, such
as aminoglycosides, which are used to treat Pseudomonas aeruginosa (PA). I conducted a …

Cystic fibrosis (CF) is the most common, fatal genetic disease in the Caucasian population
caused by loss of function mutations in gene encoding for the cystic fibrosis transmembrane …